The record
date for determining stockholders entitled to vote at the meeting will be the
close on business on March 23, 2005. PET/CT
technology improves the diagnostic accuracy and treatment management of
patients by providing surgeons, radiation oncologists and other physicians
with precise anatomical landmarks associated with the disease condition as
determined by PET.

determining survey

(OTC: IMMFF) advises that
it has acquired an 85% interest in B.C.

supplement survey

and other markets will also be pursued.

diabetes chemotherapy

DRN 11 is an excellent supplement compound that can be used alongside
prescription medications such as the US$800 million drug Metformin.

CTI Molecular Imaging Inc. Announces Date for Annual Meeting of Stockholders

Additional information is available at: http://www.ctimi.

melon breakthrough

S. As a result of better utilization of
insulin, muscle cell glucose uptake is increased.

unique immune

5 million Immune Network shares. Completed regulatory filing for
DRN 11 in Canada allows the Company to commence sales immediately. (Nasdaq: CTMI), a leading provider of positron emission tomography (PET)
equipment , molecular probes and services, today announced that it will hold
its annual meeting of stockholders on Tuesday, April 26, 2005 at the company's
headquarters located at 810 Innovation Drive, Knoxville , Tennessee.
Diseases are biological processes and it is these processes that PET examines.

chemotherapy capsules

com .

breakthrough suits

Sales
into the U.

Diabetes is the third leading cause of death in the United States with an
economic cost of over $100 billion per year and affecting 18. The company presently anticipates that it
will mail a notice of the annual meeting and related proxy materials to its
stockholders of record at March 23, 2005 on or about March 25, 2005. By improving diagnosis, PET scans aid
physicians in selecting better courses of treatment, as well as assessing
whether treatment is effective or should be changed.

survey diabetes

unique survey

-- which has a breakthrough natural health product, DRN 11, that is
proven clinically beneficial in the management of diabetes -- in exchange
for 7.

melon survey

2 million
people with an estimated 15 million not yet diagnosed.

dysfunction alternative

Pre-clinical studies have demonstrated that DRN 11 sensitizes the body's
response to its own insulin making it work more efficiently (by increasing
insulin binding and internalization). The significant clinical
benefits against all diabetes symptoms and complications have been
demonstrated through three DRN 11 clinical studies.

fights hiv

PET/CT is an imaging technology that combines the biological examination of
patients by PET with the CT images of the body's structural detail. CTI undertakes no obligation to update or
revise any forward-looking statements.

concepts diseases

, CTI Molecular Imaging,
Inc.
PET's whole-body imaging capability helps physicians improve their ability
to detect and determine the location, extent and stage of cancer, neurological
disorders and cardiac disease. Such forward-looking statements may
be identified by words such as "believe," "expect," "anticipate," "intend,"
"estimate" or similar expressions.

disorders diabetes

dysfunction infection

Immune Network Ltd.

chronic bitter

In addition , PET and PET/CT provide both the
patient and their physician with a degree of certainty that is often
unavailable through other imaging methods.

breakthrough immune

dysfunction survey

Certain matters discussed in this press release and the related conference
call constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995.

dysfunction capsules

-based Dr Nature Health Products
Inc.

About CTI Molecular Imaging:
CTI Molecular Imaging, Inc.

melon bitter

Safe Harbor Statement

The information in this release, other than historical information, may be
considered forward-looking statements within the provisions of the Private
Securities Litigation Reform Act of 1995. KNOXVILLE, Tenn . Recent published clinical
trials have shown that in a wide array of cancers, the use of PET has caused
the treatment to be changed for 15 to 50% of patients, depending on the
specific clinical question.

determining supplement

PRESS RELEASE Immune Network to Tackle Diabetes

disorders capsules

In the
DRN 11 clinical studies, reductions in the range of 15-20% in blood sugar
levels have complemented a noted quality of life benefit with no side
effects and an overall improvement in the well being and general health of
the study participants. is a leading supplier of products and services
for positron emission tomography (PET), a diagnostic imaging technology used
in the detection and treatment of cancer, neurological disorders and cardiac
disease.

capsules diabetes

Immune will now commence marketing DRN 11, the flagship product developed
by Dr Nature over the past eight years. Further information regarding risks,
uncertainties and other factors that could adversely affect CTI or cause
actual results to differ materially from those anticipated in forward-looking
statements are included in CTI's Annual Report on Form 10-K for the fiscal
year ended September 30, 2004 and Quarterly Report on Form 10 -Q for the
quarter ended December 31, 2004.

chemotherapy fights

Projection and other
forward-looking statements and management expectations regarding future
events and/or financial performance of the Company -- although given in
good faith -- are inherently uncertain and actual events and/or results may
differ materially .

About PET and PET/CT:
PET images the biology of diseases at the molecular level, often before
anatomic changes are visible or, in some cases, before symptoms appear.